FDA Returning to Original Intent on Part 11 After Confusion

Executive Briefing Series
A A
The FDA has reopened the subject of Part 11 to examine what went wrong and how to return to the agency’s original intent.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $10.00